孟鲁司特钠联合布地奈德治疗喘息性支气管炎患儿的效果分析

Effect analysis of Montelukast sodium combined with budesonide in the treatment of children with asthmatic bronchitis

目的:探究喘息性支气管炎(Pediatric asthmatic bronchitis,PAB)患儿应用孟鲁司特钠联合糖皮质激素雾化吸入治疗的效果。方法:选取2020年3月至2023年3月本院收治的80例PAB患儿作为研究对象。随机将患儿分为对照组和研究组,各40例。对照组给予布地奈德雾化吸入治疗,研究组在对照组基础上加用孟鲁司特钠治疗。分析对比两组临床疗效、症状消失时间、炎性因子[白细胞介素-6(Interleukine-6,IL-6)、降钙素原(Procalcitonin,PCT)、C反应蛋白(C-reactive protein,CRP)、血沉(Erythrocyte sedimentation rate,ESR)、白细胞计数(White blood cell,WBC)、白三烯B4(Leukotriene B4,LTB4)]、血气指标[动脉血氧分压(Arterial partial pressure of oxygen,PaO_(2))、动脉血二氧化碳分压(Partial pressure of carbon dioxide in artery,PaCO_(2))]和不良反应。结果:研究组总有效率明显高于对照组(P<0.05)。研究组气喘消失时间、咳嗽消失时间及肺部湿啰音消失时间均明显短于对照组(P<0.05)。治疗后,研究组的IL-6、PCT、CRP、ESR、WBC、LTB4水平均明显低于对照组(P<0.05);研究组PaO_(2)高于治疗前,PaCO_(2)低于对照组(P<0.05)。两组不良反应发生率对比无显著差异。结论:孟鲁司特钠联合布地奈德雾化吸入用于治疗PAB,能促进临床症状消失、控制炎症反应,改善通气功能,且安全性较高。

Objective:To investigate the effects of aerosol inhalation of Montelukast sodium combined with glucocorticoids in pediatric asthmatic bronchitis(PAB).Methods:80 children with PAB admitted to our hospital from March 2020 to March 2023 were selected as the study objects.The children were randomly divided into control group and study group,40 cases in each group.The control group was treated with budesonide aerosol inhalation,while the study group was treated with montelukast sodium on the basis of the control group.Clinical efficacy,symptom resolution time,inflammatory factors[interleukin-6(IL-6),procalcitonin(PCT),C-reactive protein(CRP),erythrocyte sedimentation rate(ESR),white blood cell count(WBC),Leukotriene B4(LTB4),blood gas indexes(arterial partial pressure of oxygen(PaO_(2)),arterial partial pressure of carbon dioxide in artery(PaCO_(2))and adverse reactions were analyzed and compared between the two groups.Results:The total effective rate of the study group was significantly higher than that of the control group(P<0.05).The disappearance time of asthma,cough and lung moist rales in the study group were significantly shorter than those in the control group(P<0.05).After treatment,the levels of IL-6,PCT,CRP,ESR,WBC and LTB4 in the study group were significantly lower than those in the control group(P<0.05).PaO_(2) in the study group was higher than that before treatment,and PaCO_(2) was lower than that in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups.Conclusion:Montelukast sodium combined with budesonide aerosol inhalation in the treatment of PAB can promote the disappearance of clinical symptoms,control inflammation,improve ventilation function,and have high safety.